|Bid||64.85 x 900|
|Ask||64.98 x 800|
|Day's range||64.18 - 65.93|
|52-week range||36.20 - 82.49|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||N/A|
|Earnings date||29 Apr 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||85.56|
Market forces rained on the parade of uniQure N.V. (NASDAQ:QURE) shareholders today, when the analysts downgraded...
(Bloomberg) -- JPMorgan Asset Management now has more than $400 million in its Thematics - Genetic Therapies fund launched in October, just before the world’s need for such technologies came into focus with the arrival of Covid-19.The fund uses natural-language processing focused on keywords in company documents along with a revenue screen to find firms that best fit the genetic-therapies theme, according to Sherene Ban, an investment specialist at JPMorgan Asset. The portfolio managers also factor in things like liquidity and quality to make decisions on the fund’s composition, Ban said in an interview Friday.The fund has a 20% one-month return that puts it in the 94th percentile among its peers, according to data compiled by Bloomberg. Of course, the biotech theme has done well generally -- the S&P Biotechnology Select Industry Index is up 9.5% this year versus a decline of 10% for the S&P Total Market Index.“We’re starting to see a lot of client interest because it actually behaved as a defensive fund” through the market turmoil of the past few months, Ban said. She noted that technologies related to genetic therapies -- such as genetic sequencing of the virus and vaccine development -- have been central to efforts to combat Covid-19, spurring price gains of stocks in the space.The fund’s top three holdings as of March 31 were Iovance Biotherapeutics Inc., Regeneron Pharmaceuticals Inc. and uniQure NV. It contains about 100 stocks to provide diversified access to the overall theme, and has about a third of its portfolio in companies with under $2 billion in market capitalization, Ban said.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
uniQure (QURE) delivered earnings and revenue surprises of 26.74% and -94.09%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
If you own shares in uniQure N.V. (NASDAQ:QURE) then it's worth thinking about how it contributes to the volatility of...
UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
It might be of some concern to shareholders to see the uniQure N.V. (NASDAQ:QURE) share price down 22% in the last...
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.